FDA Grants Ipsen’s IPN60340 Breakthrough Therapy Designation for First-Line Treatment of Elderly Patients with Acute Myeloid Leukemia
The Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to IPN60340 (ICT01), Ipsen’s investigational anti-BTN3A monoclonal antibody, in combination with venetoclax and azacitidine for first-line treatment of acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy. This regulatory acceleration